Twist Bioscience Co. (NASDAQ:TWST) Insider Dennis Cho Sells 277 Shares of Stock

Twist Bioscience Co. (NASDAQ:TWST) insider Dennis Cho sold 277 shares of the firm’s stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $40.91, for a total value of $11,332.07. Following the transaction, the insider now directly owns 111,984 shares of the company’s stock, valued at $4,581,265.44. The trade was a 0.25 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Dennis Cho also recently made the following trade(s):

• On Monday, February 3rd, Dennis Cho sold 806 shares of Twist Bioscience stock. The stock was sold at an average price of $49.35, for a total value of $39,776.10.
• On Friday, January 3rd, Dennis Cho sold 144 shares of Twist Bioscience stock. The shares were sold at an average price of $45.59, for a total value of $6,564.96.
• On Friday, December 20th, Dennis Cho sold 316 shares of Twist Bioscience stock. The shares were sold at an average price of $44.90, for a total value of $14,188.40.
• On Monday, December 16th, Dennis Cho sold 133 shares of Twist Bioscience stock. The shares were sold at an average price of $46.81, for a total value of $6,225.73.

Twist Bioscience Trading Down 6.9 %

NASDAQ:TWST opened at $36.71 on Tuesday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.62 and a current ratio of 4.96. The stock has a market cap of $2.19 billion, a price-to-earnings ratio of -10.86 and a beta of 2.15. Twist Bioscience Co. has a one year low of $27.41 and a one year high of $60.90. The business’s 50-day simple moving average is $46.54 and its 200 day simple moving average is $45.47.

Twist Bioscience (NASDAQ:TWST) last posted its earnings results on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.62) by $0.09. The company had revenue of $88.70 million during the quarter, compared to analyst estimates of $86.96 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The business’s revenue was up 24.1% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.75) earnings per share. As a group, sell-side analysts predict that Twist Bioscience Co. will post -2.12 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on TWST shares. TD Cowen reaffirmed a “buy” rating and issued a $58.00 price objective on shares of Twist Bioscience in a research report on Tuesday, November 26th. Scotiabank reaffirmed an “outperform” rating on shares of Twist Bioscience in a research report on Tuesday, February 4th. Robert W. Baird lifted their price objective on Twist Bioscience from $48.00 to $54.00 and gave the company an “outperform” rating in a research report on Tuesday, February 4th. Barclays set a $58.00 target price on Twist Bioscience and gave the company an “overweight” rating in a report on Monday, February 3rd. Finally, Wolfe Research started coverage on Twist Bioscience in a report on Friday, December 13th. They issued an “outperform” rating and a $60.00 target price on the stock. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the stock. According to MarketBeat, Twist Bioscience has a consensus rating of “Moderate Buy” and a consensus target price of $54.40.

Institutional Investors Weigh In On Twist Bioscience

Institutional investors have recently added to or reduced their stakes in the company. First Light Asset Management LLC purchased a new position in Twist Bioscience in the 4th quarter worth about $56,984,000. Thrivent Financial for Lutherans acquired a new position in shares of Twist Bioscience in the 3rd quarter valued at about $43,992,000. Marshall Wace LLP grew its stake in shares of Twist Bioscience by 15,927.8% in the 4th quarter. Marshall Wace LLP now owns 846,107 shares of the company’s stock valued at $39,319,000 after buying an additional 840,828 shares in the last quarter. State Street Corp grew its stake in shares of Twist Bioscience by 19.9% in the 3rd quarter. State Street Corp now owns 3,167,353 shares of the company’s stock valued at $143,101,000 after buying an additional 526,028 shares in the last quarter. Finally, Wellington Management Group LLP grew its stake in shares of Twist Bioscience by 188.5% in the 3rd quarter. Wellington Management Group LLP now owns 797,737 shares of the company’s stock valued at $36,042,000 after buying an additional 521,272 shares in the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.